Efficacy of percutaneous ethanol injection therapy for secondary hyperparathyroidism in patients on hemodialysis as evaluated by parathyroid hormone levels according to K/DOQI guidelines

Therapeutic Apheresis and Dialysis

Volumn 9, Issue 1, 2005, Pages 48-52

  Tanaka, Motoko ^a   Itoh, Kazuko ^a   Matsushita, Kazunori ^a   Matsushita, Kazutaka ^a   Fukagawa, Masafumi ^b  

^a Akebono Clinic   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hemodialysis; K DOQI guidelines; Percutaneous ethanol injection therapy; Secondary hyperparathyroidism

Indexed keywords

ALCOHOL; CALCIUM ION; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGED; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; FEMALE; HEMODIALYSIS; HUMAN; MALE; PARATHYROID HORMONE BLOOD LEVEL; PERCUTANEOUS ETHANOL INJECTION THERAPY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SCLEROTHERAPY; SECONDARY HYPERPARATHYROIDISM;

CALCIUM; CASE-CONTROL STUDIES; ETHANOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID GLANDS; PARATHYROID HORMONE; PHOSPHORUS; PRACTICE GUIDELINES; RENAL DIALYSIS; TIME FACTORS;

EID: 15344348869     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1774-9987.2005.00214.x     Document Type: Review

References (26)

1. Patient Registration Committee, Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan (as of 31 December 2001). Ther Apher Dial 2004;8:1-32.
2. Malluche H, Faugere MC. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 1990;8:193-211.
3. Tominaga Y, Grimelius L, Falkmer UG, Johansson H, Falkmer S. DNA ploidy pattern of parathyroid parenchymal cells in renal secondary hyperparathyroidism with relapse. Anal Cell Pathol 1991;3:325-33.
4. Tominaga Y, Tanaka Y, Sato K et al. Recurrent renal hyperparathyroidism and DNA analysis of autografted parathyroid tissue. World Surg 1992;16:595-603.
5. Tominaga Y, Tanaka Y, Sato K, Nagasaka T, Takagi H. Histology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997;13:78-86.
6. Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, Durueke TB. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995;95:2047-53.
7. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92:1436-43.
8. Koike T, Fukuda N, Fukagawa M, Ohta K, Kurokawa K. Correlation of enhanced cell proliferation with decreased density of vitamin D receptor in situ in parathyroid hyperplasia in chronic dialysis patients. Nephrology 1997;3:279-84.
9. 2+ sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81:1598-606.
10. Gogusev J, Duchambon P, Hory B et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997;51:328-36.
11. Fukagawa M, Tominaga Y, Kitaoka M, Kakuta T, Kurokawa K. Medical and surgical aspects of parathyroidectomy. Kidney Int 1999;73:S65-9.
12. Fukagawa M, Kitaoka M, Tominaga Y et al. Japanese Society for parathyroid intervention: guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients. Nephrol Dial Transplant 2003;18:S31-3.
13. Fukagawa M, Kazama JJ, Shigematsu T. Management of patients with advanced secondary hyperparathyroidism: the Japanese approach. Nephrol Dial Transplant 2002;17:1553-7.
14. National Kidney Foundation. K/DOQI clinical guideline for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-202.
15. Tominaga Y, Numano M, Tanaka Y et al. Surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997;13:87-96.
16. Fukagawa M, Kitaoka M, Inazawa T, Kurokawa K. Imaging of the parathyroid in chronic renal failure: diagnostic and therapeutic aspects. Curr Opin Nephrol Hypertens 1997; 6:349-55.
17. Fukagawa M, Kitaoka M, Kurokawa K. Ultrasonographic intervention of parathyroid hyperplasia in chronic dialysis patients: a theoretical approach. Nephrol Dial Transplant 1996;11:125-9.
18. Kitaoka M, Fukagawa M, Ogata E, Kurokawa K. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int 1994;46:1110-17.
19. Kakuta T, Fukagawa M, Fujisaki T et al. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy (percutaneous ethanol injection therapy) guided by color Doppler flow mapping in chronic dialysis patients. Am J Kidney Dis 1999;33:1091-9.
20. Kitaoka M, Fukagawa M, Fukuda N, Yi H, Kurokawa K. Direct injections of calcitriol into parathyroid hyperplasia in chronic dialysis patients with severe parathyroid hyperfunction. Nephrology 1995;1:563-8.
21. Kitaoka M, Onoda N, Kitamura H, Koiwa F, Tanaka M, Fukagawa M. Percutaneous calcitriol injection therapy (PCIT) of secondary hyperparathyroidism: multicentre trial. Nephrol Dial Transplant 2003;18:iii38-41.
22. Shiizaki K, Hatamura I, Negi S et al. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int 2003;64:992-1003.
23. Gagne ER, Urena P, Leite-Silva S et al. Short- and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 1992;3:1008-17.
24. Yajima A, Ogawa Y, Ikehara A, Tominaga T, Inou T, Otsubo O. Development of low-turnover bone diseases after parathyroidectomy and auto transplantation. Int J Urol 2001;8:S76-9.
25. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000;35:1226-37.
26. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8.